

## History of Phase II Clinical Trials with ACC Patients (Updated August 2018)

Drug	Targets	ACC Patients	Objective Response	Median Progression Free Survival	Stable Disease Duration	Progression Required	Publication Year & Link
<a href="#">Lenvatinib</a> (Lenvima)	VEGFR, FGFR, PDGFR, KIT	32	16%	17.5 months		Yes	<a href="#">2018*</a>
<a href="#">Lenvatinib</a> (Lenvima)	VEGFR, FGFR, PDGFR, KIT	28	11%	9 months		Yes	<a href="#">2018*</a>
<a href="#">Apatanib</a>	VEGFR	56	47% (downward revision pending)			No	<a href="#">2018*</a>
<a href="#">Regorafenib</a>	FGFR, VEGFR, PDGFR, KIT	38	0%		45% > 6 months	Yes	<a href="#">2016*</a>
<a href="#">Dovitinib</a>	FGFR, VEGFR, PDGFR	34	6%	8.2 months	65% > 4 months	Yes	<a href="#">2017</a>
<a href="#">Dovitinib</a>	FGFR, VEGFR, PDGFR	32	3%	6 months	80% > 4 months	Yes	<a href="#">2015</a>
<a href="#">Axitinib</a>	VEGFR, PDGFR, KIT	33	9%	5.7 months	39% > 6 months	Yes	<a href="#">2016</a>
<a href="#">Pazopanib</a>	VEGFR, PDGFR, KIT	45	2%	5.9 months	46% > 6 months	Yes	<a href="#">2016*</a>
<a href="#">Sorafenib</a> (Nexavar)	VEGFR, PDGFR, KIT, RAF, RET	19	11%	8.9 months		No	<a href="#">2016</a>
<a href="#">Sorafenib</a> (Nexavar)	VEGFR, PDGFR, KIT, RAF, RET	19	11%	11.3 months	69% > 6 months, 46% > 1 year	No	<a href="#">2015</a>
<a href="#">Sunitinib</a> (Sutent)	VEGFR, PDGFR, KIT, RET	13	0%	7.2 months	62% > 6 months	Yes	<a href="#">2011</a>
<a href="#">Pembrolizumab</a> (Keytruda) and <a href="#">Vorinostat</a> (Zolinza)	PD-1, HDAC	12	8%			Yes	<a href="#">2018*</a>
<a href="#">Vorinostat</a> (Zolinza)	HDAC	30	7%	11.4 months	46% > 1 year	No (90% Yes)	<a href="#">2017</a>
<a href="#">BBI503</a>	Cancer stemness	13	0%		38% > 6 months	No	<a href="#">2016*</a>
<a href="#">MK-2206</a>	AKT	14	0%	9.2 months	16% > 1 year	Yes	<a href="#">2015*</a>
<a href="#">Nelfinavir</a>	AKT, HIV protease	15	0%	5.5 months	13% > 6 months	Yes	<a href="#">2015</a>
<a href="#">Everolimus</a> (Afinitor)	mTOR	31	0%	11.2 months	66% > 4 months	Yes	<a href="#">2014</a>
<a href="#">Dasatinib</a> (Sprycel)	BCR-ABL, SRC, KIT	40	3%	4.8 months	36% > 6 months	Yes	<a href="#">2015</a>
<a href="#">Imatinib</a> & <a href="#">Cisplatin</a>	BCR-ABL, KIT, PDGFR	28	11%	15 months	79% > 6 months, 57% > 1 year	No	<a href="#">2011</a>
<a href="#">Imatinib</a> (Gleevec)	BCR-ABL, KIT, PDGFR	12	0%	5.7 months	50% > 5.7 months	No	<a href="#">2008</a>
<a href="#">Imatinib</a> (Gleevec)	BCR-ABL, KIT, PDGFR	10	0%				<a href="#">2007</a>
<a href="#">Imatinib</a> (Gleevec)	BCR-ABL, KIT, PDGFR	15	0%	2.5 months	13% > 6 months	No	<a href="#">2005</a>
<a href="#">Gefitinib</a> (Iressa)	EGFR	18	0%	4.3 months	39% > 9 months	No	<a href="#">2015</a>



## Adenoid Cystic Carcinoma Research Foundation

<a href="#">Cetuximab</a> (Erbix) EGFR	23	0%	6 months	52% > 6 months	No	<a href="#">2009</a>
<a href="#">Lapatinib</a> (Tykerb) EGFR, HER2	19	0%	3.5 months	35% > 6 months	Yes	<a href="#">2007</a>
<a href="#">Bortezomib</a> (Velcade) NFKB, 26S Proteasome	21	0%	6.4 months	18% > 1 year	Yes	<a href="#">2011</a>
<a href="#">Eribulin</a> Chemotherapy	11	9%			Yes	<a href="#">2018</a>
<a href="#">Gemcitabine</a> & <a href="#">Cisplatin</a> Chemotherapy	10	20%			No	<a href="#">2009</a>
<a href="#">Gemcitabine</a> Chemotherapy	21	0%		48% > 6 months	No	<a href="#">2008</a>
<a href="#">Paclitaxel</a> Chemotherapy	13	0%		38% > 6 months	No	<a href="#">2006</a>

\* Abstract (not article)